<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; China</title>
	<atom:link href="http://www.tapanray.in/tag/china/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma’s Digital Initiatives In India: A Missing Link</title>
		<link>http://www.tapanray.in/pharmas-digital-initiatives-in-india-a-missing-link/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmas-digital-initiatives-in-india-a-missing-link</link>
		<comments>http://www.tapanray.in/pharmas-digital-initiatives-in-india-a-missing-link/#comments</comments>
		<pubDate>Mon, 05 Jul 2021 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[EHR]]></category>
		<category><![CDATA[electronic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HHS]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[IGHI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Initiative]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[Missing]]></category>
		<category><![CDATA[mission]]></category>
		<category><![CDATA[NDHM]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[providers]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[record]]></category>
		<category><![CDATA[service]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10543</guid>
		<description><![CDATA[An interesting study &#8211; designed to investigate the challenges that Health and Human Services (HHS) organizations face in implementing digital and data solutions, stands out today &#8211; for many reasons. One such being, this ‘multi-country survey’ project team had no &#8230; <a href="http://www.tapanray.in/pharmas-digital-initiatives-in-india-a-missing-link/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmas-digital-initiatives-in-india-a-missing-link/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shifting Pharma Supply Chain Strategy From Global To Local</title>
		<link>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shifting-pharma-supply-chain-strategy-from-global-to-local</link>
		<comments>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/#comments</comments>
		<pubDate>Mon, 08 Jun 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Procurement]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reevaluating]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vulnerability]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10120</guid>
		<description><![CDATA[Alongside large-scale disruptions of many critical industrial operations, Covid-19 global pandemic took the wind out of the sail of pharma supply chain, as well, at the very onset of lockdowns. This happened in many countries around the world, including the &#8230; <a href="http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Post Covid-19 Lockdown: Is Pharma Industry Ready?</title>
		<link>http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=post-covid-19-lockdown-is-pharma-industry-ready</link>
		<comments>http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/#comments</comments>
		<pubDate>Mon, 27 Apr 2020 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[customer-centric]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[herd-immunity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[Oxford]]></category>
		<category><![CDATA[physical]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ready]]></category>
		<category><![CDATA[remdesivir]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Social-distancing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10033</guid>
		<description><![CDATA[It’s over a month now since national lockdown in India came into force to win the war against Covid-19. Many promises and apprehensions about whether or not Covid-19 will keep ravaging human life, continue surfacing. As it appears today, whatever &#8230; <a href="http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Acid Test For Excellence in Crisis Leadership</title>
		<link>http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=acid-test-for-excellence-in-crisis-leadership</link>
		<comments>http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/#comments</comments>
		<pubDate>Mon, 13 Apr 2020 00:07:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[21 day]]></category>
		<category><![CDATA[Acid]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Italy]]></category>
		<category><![CDATA[Juty]]></category>
		<category><![CDATA[leader]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[Mask]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Outbreak]]></category>
		<category><![CDATA[PPE]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[test]]></category>
		<category><![CDATA[turnaround]]></category>
		<category><![CDATA[United Staes]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9986</guid>
		<description><![CDATA[On April 12, 2020 – in the morning of the day 19 of the national lockdown, India’s total number of Coronavirus positive cases reached 8,504 with 289 deaths. The country&#8217;s trajectory is reportedly  steeper than most Asian peers, such as Singapore, Japan, and Indonesia. &#8230; <a href="http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Coronavirus Outbreak: Drug Shortage, Treatment And Unease – A Review</title>
		<link>http://www.tapanray.in/coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review</link>
		<comments>http://www.tapanray.in/coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review/#comments</comments>
		<pubDate>Mon, 09 Mar 2020 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[26 drugs]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[bullet]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[disruption]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Drug Shortage]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[hand]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[import ban]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[masks]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[N95]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[Outbreak]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[sanitizer]]></category>
		<category><![CDATA[serum Institute]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transmitted]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[Unease]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9903</guid>
		<description><![CDATA[The Coronavirus outbreak has reached a &#8220;decisive point&#8221; and has &#8220;pandemic potential&#8221;, said the Director General of the World Health Organization (W.H.O), reportedly, on February 27, 2020, urging governments to act swiftly and aggressively to contain the virus. He further added, &#8220;We are &#8230; <a href="http://www.tapanray.in/coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s Preparedness Against Biological Threats</title>
		<link>http://www.tapanray.in/indias-preparedness-against-biological-threats/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-preparedness-against-biological-threats</link>
		<comments>http://www.tapanray.in/indias-preparedness-against-biological-threats/#comments</comments>
		<pubDate>Mon, 24 Feb 2020 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2019-nCoV]]></category>
		<category><![CDATA[allocation]]></category>
		<category><![CDATA[biological]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[building]]></category>
		<category><![CDATA[capability]]></category>
		<category><![CDATA[Capacity]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[nCoV]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[preparedness]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[quarantine]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threats]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9888</guid>
		<description><![CDATA[Recent Coronavirus outbreak poses a &#8216;very grave threat to the rest of the world&#8217; &#8211; the head of the World Health Organization (WHO), reportedly said on February 11, 2020. Earlier, on January 28, 2020, it had changed the viruses’ risk-status from ‘moderate’ to ‘high’. As &#8230; <a href="http://www.tapanray.in/indias-preparedness-against-biological-threats/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-preparedness-against-biological-threats/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Criticality of Drug Quality In The Moment Of Truth</title>
		<link>http://www.tapanray.in/criticality-of-drug-quality-in-the-moment-of-truth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=criticality-of-drug-quality-in-the-moment-of-truth</link>
		<comments>http://www.tapanray.in/criticality-of-drug-quality-in-the-moment-of-truth/#comments</comments>
		<pubDate>Mon, 10 Feb 2020 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['The Moment Of Truth']]></category>
		<category><![CDATA[2019-nCoV]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ARV]]></category>
		<category><![CDATA[CDER]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[criticality]]></category>
		<category><![CDATA[dependence]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[letters]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Unites States]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[warning]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9870</guid>
		<description><![CDATA[When global health emergencies strike unannounced &#8211; in the scale and magnitude of new coronavirus, it shakes the health care system of all countries, in varying degree though, irrespective of the robustness of the economy. In such situation, the robustness &#8230; <a href="http://www.tapanray.in/criticality-of-drug-quality-in-the-moment-of-truth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/criticality-of-drug-quality-in-the-moment-of-truth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>China Coronavirus And API Sourcing &#8211; A Threat… Or An Opportunity For India?</title>
		<link>http://www.tapanray.in/china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india</link>
		<comments>http://www.tapanray.in/china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india/#comments</comments>
		<pubDate>Mon, 03 Feb 2020 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2019-nCoV]]></category>
		<category><![CDATA[Active]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[green]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Kerala]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[shoots]]></category>
		<category><![CDATA[sourcing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9858</guid>
		<description><![CDATA[‘2015 – Year of Active Pharmaceutical Ingredients’ (API), announced the Government of India by a Press Release on February 25, 2015. This came after ascertaining that over-dependence on imports of bulk drugs or API, especially from China, is detrimental to India’s health &#8230; <a href="http://www.tapanray.in/china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Improving Drug Quality in India &#8211; A Bizarre Intent</title>
		<link>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-improving-drug-quality-in-india-a-bizarre-intent</link>
		<comments>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/#comments</comments>
		<pubDate>Sun, 28 Jan 2018 23:43:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[bizarre]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[facilities]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inspection]]></category>
		<category><![CDATA[Inspectors]]></category>
		<category><![CDATA[Kerala]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Misplaced]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[plants]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Shortages]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8778</guid>
		<description><![CDATA[On January 16, 2017, quoting a Government source, a media report revealed, “India&#8217;s drug regulator is looking to inspect US pharmaceutical facilities, making critical medicines so that only high-quality products are imported from them.” This intent follows a similar decision &#8230; <a href="http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Global Generic Drug Market Slowing Down?</title>
		<link>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-global-generic-drug-market-slowing-down</link>
		<comments>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/#comments</comments>
		<pubDate>Sun, 04 Jun 2017 23:55:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[elf]]></category>
		<category><![CDATA[expiration]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inflicted]]></category>
		<category><![CDATA[injury]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[murmurs]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[slowing]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8258</guid>
		<description><![CDATA[Driven by a strong environmental headwind, both within and outside the country, several pharma companies in India have recently started raising a red flag on their future earning guidance for the stock market, though citing quite different reasons altogether. Quoting &#8230; <a href="http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
